- OncoTree
- VGCT
Loading cancer entity…
Loading cancer entity…
Clinical trials
27 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02689219 | Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors | terminated | Phase 2 | 18 | Nabil AdraOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT00042952 |
| Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer |
| terminated |
| Phase 2 |
| 32 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jan 17, 2013 |
| clinicaltrials |
Data updated 23 days agoSource updated Dec 10, 2019source: clinicaltrials